Bausch Health Q3 adjusted EPS jumps 53%, beats estimates; FY outlook raised
BHC•Bausch Health said third-quarter revenue rose 10% year over year and adjusted EPS increased 53% to $1.77, above the $1.29 estimate. It raised its 2026 guidance, projecting revenue of $10.975 billion to $11.175 billion and adjusted EBITDA of $4.315 billion to $4.415 billion.
1. Quarterly results
Bausch Health reported third-quarter adjusted EPS of $1.77, up 53% year over year and above the $1.29 analyst estimate. Revenue rose 10% year over year, while adjusted EBITDA was $1.31 billion versus an estimate of $1.05 billion.
2. Raised 2026 outlook
The company raised its full-year 2026 revenue, adjusted EBITDA and adjusted cash flow guidance. It expects revenue of $10.975 billion to $11.175 billion, up 7% to 9% from the prior year, and adjusted EBITDA of $4.315 billion to $4.415 billion, up 12% to 14%. Growth in the Salix segment, led by Xifaxan, was the primary contributor to revenue gains. Solta Medical revenue growth was driven by an acquisition of a distributor in China, though organic sales declined; double-digit Dermatology growth also contributed to gains in the Diversified segment.
